GRI Bio, Inc. Common Stock

GRI

GRI Bio, Inc. is a biotechnology company focused on developing therapies targeting autoimmune and inflammatory diseases. The company leverages a proprietary platform to identify and develop novel biologics aimed at modulating immune responses, with an emphasis on improving patient outcomes in conditions with unmet medical needs.

$1.30 -0.76 (-36.89%)
đźš« GRI Bio, Inc. Common Stock does not pay dividends

Company News

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
GlobeNewswire Inc. • Marc Hertz, Phd • July 31, 2025

GRI Bio participated in a virtual investor segment discussing its Phase 2a study interim biomarker data for Idiopathic Pulmonary Fibrosis, highlighting potential therapeutic advances in treating inflammatory and fibrotic diseases using NKT cell modulators.

Top 4 Health Care Stocks That Are Preparing To Pump This Month
Benzinga • Avi Kapoor • February 23, 2024

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perfo...

Related Companies